Afya heads into its third-quarter report with a stock that has already absorbed a lot of bad news. Shares have fallen about 21% since the company's last update, roughly 18 percentage points worse than the S&P 500. The question for November 12 is whether the investment-driven margin compression management described last quarter is a temporary, controlled dip or the start of a longer slide in earnings power for Brazil's largest medical school operator.

The Street expects earnings of $0.36 per share on revenue of about $187.4 million. That implies a quarter of decent top-line growth, near 10% year over year, paired with slightly lower profits, as EPS is forecast to slip about 3% from $0.37 a year ago. The gap between those two figures is the story in miniature: revenue is still expanding, but spending on continuing education and digital products is consuming the gains. Investors should also keep in mind that dollar-based estimates can be flattered or hurt by currency moves, so the local-currency growth rate, which slowed to 7% in the first half from 12% to 13% in 2025, is the better gauge of underlying momentum.

Management reaffirmed full-year adjusted EBITDA guidance of R$1.7 billion to R$1.8 billion, but the arithmetic is uncomfortable. First-half results annualize near the top of that range, which means the guidance itself implies a softer second half. If third-quarter EBITDA tracks toward the middle of the range, that would merely confirm what management has already signaled. A result that pushes the full year toward the low end would suggest the investment cycle is costing more than planned, while holding near the top would argue that the margin pressure, which took first-half EBITDA margin down about 190 basis points to 46.2%, is leveling off.

Segment trends will matter more than the headline numbers. Continuing education revenue growth halved to 5% even as student counts climbed 23%, because learners are shifting toward shorter, cheaper programs. Another quarter of strong enrollment with stalled revenue would reinforce the view that this business is buying volume at the expense of pricing. The medical practice solutions unit is the bigger worry. Whitebook is losing paying users and monthly actives to free AI tools, and management chose to cut prices to defend the audience while pushing any monetization recovery out to 2027. Segment growth of just 2% leaves little cushion, so further declines in active users or ecosystem users, which slipped to 295,000, would challenge the idea that price cuts can stabilize engagement. The bright spot is clinical management software, where paying users grew 20% to more than 50,000; continued strength there would show Afya has a credible digital growth engine beyond Whitebook. In the core medical schools, the average ticket eased last quarter, and evidence that it is holding steady would ease concerns about pricing in the most profitable part of the business.

There are supportive offsets. The lower expected tax rate of about 10% for 2026, down from a prior assumption closer to 15%, should help net income, and buybacks continue to shrink the share count. An injunction restoring previously suspended seats eased regulatory pressure, though fresh ENAMED results due in early December will shape the 2027 intake, so any commentary on that front deserves attention.

Sentiment has turned noticeably less negative, improving from strongly bearish before the last report to only mildly bearish now, even as the stock sits well below its 200-day moving average of $14.15 and not far above its post-earnings low of $9.66. That combination suggests expectations have reset lower. The report will hinge on whether second-half margins soften only as much as guidance implies, and whether Afya can show that its digital and continuing education investments are building toward future revenue rather than simply compressing today's profits.